drug · small molecule
sevasemten
Phase 3updated 6mo agoby $EWTX Edgewise Therapeutics, Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.
indications
indications
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
Trials studying sevasemten
- phase2Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- phase2Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- phase2A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- phase2Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
- phase1A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
- phase1A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
News(6)
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downThe deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.biopharma_dive · 10d ago
- Servier’s $1.6B muscular dystrophy bet on Edgewise delivers quick-fire pivotal failureServier’s decision to bet $1.55 billion on Edgewise Therapeutics’ muscular dystrophy program ahead of pivotal data has backfired. Five months after striking the deal, the French drugmaker has repor…fiercebiotech · 13d ago
- STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major testServier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.stat · 13d ago
- Servier's $1.5B bet on Edgewise drug fails five months inThe muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial. The drug, called sevasemten, failed the primary and secondary endpoints in the GRAND…endpoints · 13d ago
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.biopharma_dive · 5mo ago
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.stat · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that